Search

Objective: To investigate whether the combination of neoadjuvant hyperthermic intraperitoneal chemotherapy (NHIPEC) plus intravenous neoadjuvant chemotherapy (IV NACT) has superior efficacy to IV NACT alone. Design: Retrospective cohort study. Setting: Two tertiary referral university hospitals. Population Patients with ovarian cancer who received NACT‐interval debulking surgery (IDS) between 2012 and 2020. Methods: The tumour response to NACT was evaluated with the chemotherapy response score (CRS) system. Survival outcomes were compared. Main outcome measures: CRS 3, progression‐free survival (PFS), and overall survival (OS). Results: In total, 127 patients were included, and 46 received NHIPEC plus IV NACT. The addition of NHIPEC was independently associated with an increased likelihood of CRS 3 (p = 0.033). Patients who received NHIPEC + IV NACT had significantly improved PFS compared with those who received IV NACT alone (median PFS: 22 versus 16 months, p < 0.001). The use of NHIPEC was identified as an independent predictor of PFS (p < 0.0001). OS did not differ significantly between treatment groups (p = 0.062), although a trend favouring NHIPEC was noted. Incidence of grade 3–4 adverse events and the surgical complexity score of IDS were similar between the two groups. Conclusions: Compared with IV NACT alone, the combination of NHIPEC and IV NACT resulted in improved tumour response and longer PFS. The addition of NHIPEC did not increase the risk of adverse effects or affect the complexity of IDS. [ABSTRACT FROM AUTHOR]

Background Recent reports have characterized virological and clinical features of the novel reassortant avian-origin influenza A (H7N9) virus. However, cardiovascular involvement during H7N9 infection is still unclear. In this study, we evaluate cardiac injury among H7N9-infected patients. Materials and Methods A total of 40 patients who were laboratory-confirmed with H7N9 infection were retrospectively included and grouped by Acute Physiology and Chronic Health Evaluation II ( APACHE II) score into four subgroups I(0-10), II(11-20), III(21-30) and IV(31-71). Cardiovascular complications and markers of cardiac injury including creatinine kinase ( CK), CK iso-enzyme ( CK- MB), cardiac troponin I ( cTNI) and brain natriuretic peptide ( BNP) were assessed. Electrocardiogram ( ECG) and echocardiography ( ECHO) were also performed. Results Half of patients manifested with cardiovascular complications, with hypotension (47·5%) and heart failure (40·0%) the most prevalent. CK, CK- MB and cTNI showed marked increase with H7N9 virus infection but significantly decreased after H7N9 viral tests turned negative. More than half of patients presented with an abnormal ECG, but most of them are benign changes. ECHO examination showed different degree of impairment of cardiac function. Pulmonary artery systolic pressure was increased in all groups. Cardiac damage was more evident in patients with higher APACHE II score. Conclusions H7N9 virus exerts a transient impairment on the cardiovascular system. Patients with a higher APACHE II score are more susceptible to cardiac damage. [ABSTRACT FROM AUTHOR]

Objective: To investigate whether the combination of neoadjuvant hyperthermic intraperitoneal chemotherapy (NHIPEC) plus intravenous neoadjuvant chemotherapy (IV NACT) has superior efficacy to IV NACT alone., Design: Retrospective cohort study., Setting: Two tertiary referral university hospitals., Population: Patients with ovarian cancer who received NACT-interval debulking surgery (IDS) between 2012 and 2020., Methods: The tumour response to NACT was evaluated with the chemotherapy response score (CRS) system. Survival outcomes were compared., Main Outcome Measures: CRS 3, progression-free survival (PFS), and overall survival (OS)., Results: In total, 127 patients were included, and 46 received NHIPEC plus IV NACT. The addition of NHIPEC was independently associated with an increased likelihood of CRS 3 (p = 0.033). Patients who received NHIPEC + IV NACT had significantly improved PFS compared with those who received IV NACT alone (median PFS: 22 versus 16 months, p < 0.001). The use of NHIPEC was identified as an independent predictor of PFS (p < 0.0001). OS did not differ significantly between treatment groups (p = 0.062), although a trend favouring NHIPEC was noted. Incidence of grade 3-4 adverse events and the surgical complexity score of IDS were similar between the two groups., Conclusions: Compared with IV NACT alone, the combination of NHIPEC and IV NACT resulted in improved tumour response and longer PFS. The addition of NHIPEC did not increase the risk of adverse effects or affect the complexity of IDS., (© 2022 John Wiley & Sons Ltd.)